S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-α) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases

Increased interferon-α (IFN-α) production is a critical component in the pathophysiology of systemic lupus erythematosus (SLE) and other rheumatic autoimmune diseases. Herein, we report the characterization of S95021, a fully human IgG1 anti–IFN–α monoclonal antibody (mAb) as a novel therapeutic can...

Descripción completa

Detalles Bibliográficos
Autores principales: Duguet, Fanny, Ortega-Ferreira, Céline, Fould, Benjamin, Darville, Hélène, Berger, Sylvie, Chomel, Agnès, Leclerc, Grégory, Kisand, Kai, Haljasmägi, Liis, Hayday, Adrian C., Desvaux, Emiko, Nony, Emmanuel, Moingeon, Philippe, De Ceuninck, Frédéric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Research paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972961/
https://www.ncbi.nlm.nih.gov/pubmed/33748735
http://dx.doi.org/10.1016/j.jtauto.2021.100093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7972961/
https://www.ncbi.nlm.nih.gov/pubmed/33748735
http://dx.doi.org/10.1016/j.jtauto.2021.100093

Ejemplares similares